At Otsuka, the health and wellbeing of patients is our primary focus, and everything we do as a company is geared towards achieving it. This means that we research, develop and provide pharmaceuticals that make a real difference to people’s lives in areas of unmet medical need, such as in central nervous system (CNS) disorders, endocrinology, nephrology, oncology and more. We always aim to help people by trying to create products that nobody else has thought of, rather than create more of the same products that already exist in an overcrowded market. We regard ourselves as a brave and passionate company that is willing to take on challenges that other companies shy away from, such as the search for anti-infectives to treat tuberculosis, many strains of which are drug-resistant and can prove fatal. At Otsuka, we are willing to take a long-term view when it comes to investing in researching diseases and disorders that are difficult to treat and that can seriously affect people’s lives: for example, schizophrenia or autosomal dominant polycystic kidney disease (ADPKD). We understand that it can take a decade or longer to come up with the answers and subsequently provide the medicines that can alleviate or prevent suffering, but perseverance is a trait that is found in all our employees. For example, one of our most successful products, an anti-psychotic drug that is now one of world’s best-selling medications, took more than 25 years from its initial concept to being available to millions of people worldwide. Otsuka provided the optimum environment to let our researchers persevere over a long period while the answers remained elusive, leading to the eventual launch of the drug in 2002; it has offered a new treatment option for millions of schizophrenia and bipolar disorder sufferers. By giving our people time to be curious and take untravelled paths, Otsuka is working today towards creating the solutions for tomorrow to improve the health of millions of people.